Status:
COMPLETED
A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old
Lead Sponsor:
Enimmune Corporation
Conditions:
Enterovirus Infections
Eligibility:
All Genders
6-6 years
Phase:
PHASE2
Brief Summary
The objectives of this study are to evaluate the immune response and safety profiles of two injections of EV71 vaccine administrated with or without adjuvant AlPO4 at 0.5-μg, 1-μg, 2-μg and 5-μg dose ...
Eligibility Criteria
Inclusion
- Healthy children aged from 3 to 6 years old (i.e. ≥ 3 years old and \< 7 years old) for Part A; from 6 to 35 months old (i.e. ≥ 6 months old and \< 36 months old) for Part B at the time of first vaccination.
- Subject's guardians were able and willing to comply with study procedures and give written informed consent.
- Subject was able and could comply with the requirements of the protocol.
- Subject with body temperature ≤38°C.
Exclusion
- Subject with previous known exposure to Enterovirus 71 (EV71).
- Subject with a history of herpangina, hand-foot-mouth disease, acute hemorrhagic conjunctivitis associated with enterovirus infection in the past 3 months.
- Subject with gestation \< 37 weeks.
- Subject with birth weight \<2.5 kg.
- Subject with a history of hypersensitivity to vaccines, or a history of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- Family history of seizures or progressive neurological disease.
- Family history of congenital or hereditary immunodeficiency.
- Severe malnutrition or dysgenopathy.
- Major congenital defects or serious chronic illness, including perinatal brain damage.
- Subject diagnosed of having autoimmune disease (e.g., celiac disease, type I diabetes, lupus (SLE), juvenile dermatomyositis, scleroderma, juvenile idiopathic arthritis (JIA), immune (or idiopathic) thrombocytopenia purpura).
- Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws.
- Any acute infections 7 days prior to administrate the first vaccination.
- Use of any investigational product (including drug, vaccine) within 30 days prior to vaccination or planned use during the study period.
- Administration of any attenuated live vaccine within 7 days prior to vaccination.
- Use of immunoglobulins or any blood products within 3 months prior to vaccination or planned use during the study period.
- Chronic administration (defined as \> 14 days) of immunosuppressants or other immunomodulators or systemic corticosteroids within 6 months prior to vaccination.
- Under anti-tuberculosis prevention or therapy.
- Any condition that in the opinion of the investigator may interfere with the evaluation of study objectives.
Key Trial Info
Start Date :
December 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT02777411
Start Date
December 1 2014
End Date
January 1 2016
Last Update
November 30 2016
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
China Medical University Hospital
Taichung, Taiwan
2
National Taiwan University Hospital
Taipei, Taiwan
3
Taipei Veterans General Hospital
Taipei, Taiwan
4
Linkou Chang Gung Memorial Hospital
Taoyuan District, Taiwan